Literature DB >> 7525573

Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction.

T Ball1, S Vrtala, W R Sperr, P Valent, M Susani, D Kraft, R Valenta.   

Abstract

An epitope expression cDNA library was constructed from the randomly fragmented cDNA coding for Phl p I, the major grass pollen allergen. Using IgE from allergic patients, epitope clones were isolated and immunodominant fragments were selected. Among three epitope clones coding for a similar region of Phl p I, one clone expressed a 15-amino-acid epitope which was target for IgE antibodies from approximately 30% of grass pollen allergic patients. According to the prevalence of grass pollen allergy, 22% of all allergic patients are expected to display IgE reactivity with this epitope. Although the purified recombinant epitope specifically bound IgE, it did not release histamine from basophiles of most grass pollen allergic patients and thus represents an IgE hapten. Immunodominant IgE haptens may be useful as therapeutic agents to saturate mast cell-bound IgE prior to allergen exposure and may represent candidates for a safe immunotherapy of allergic diseases by reducing anaphylactic side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525573

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Epitope and mimotope for an antibody to the Na, K-ATPase.

Authors:  T Pacholczyk; K J Sweadner
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

2.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

3.  Immunotherapy with B cell epitopes ameliorates inflammatory responses in Balb/c mice.

Authors:  P Sharma; S N Gaur; N Arora
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

Review 4.  New strategies for allergen T cell epitope identification: going beyond IgE.

Authors:  Véronique Schulten; Bjoern Peters; Alessandro Sette
Journal:  Int Arch Allergy Immunol       Date:  2014-11-15       Impact factor: 2.749

5.  Crystal structure and activities of EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize.

Authors:  Neela H Yennawar; Lian-Chao Li; David M Dudzinski; Akira Tabuchi; Daniel J Cosgrove
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

Review 6.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

7.  Identification and expression of an allergen Asp f 13 from Aspergillus fumigatus and epitope mapping using human IgE antibodies and rabbit polyclonal antibodies.

Authors:  L P Chow; S L Liu; C J Yu; H K Liao; J J Tsai; T K Tang
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

8.  Molecular and immunological characterization and IgE epitope mapping of Pen n 18, a major allergen of Penicillium notatum.

Authors:  Chia-Jung Yu; Yen-Ming Chen; Song-Nan Su; Farhad Forouhar; Shu-Hua Lee; Lu-Ping Chow
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

Review 9.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

10.  Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy.

Authors:  T E Twaroch; M Focke; K Fleischmann; N Balic; C Lupinek; K Blatt; R Ferrara; A Mari; C Ebner; P Valent; S Spitzauer; I Swoboda; R Valenta
Journal:  Clin Exp Allergy       Date:  2012-06       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.